| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 24 |
| 1 | PACLITAXEL | 23 |
| 2 | PACLITAXEL (AIBUMIN-BOUND) | 23 |
| 3 | PERTUZUMAB | 9 |
| 4 | TRASTUZUMAB | 9 |
| 5 | DOXORUBICIN | 8 |
| 6 | BEVACIZUMAB | 7 |
| 7 | PEMBROLIZUMAB | 5 |
| 8 | NIVOLUMAB | 4 |
| 9 | DURVALUMAB | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BEVACIZUMAB-MALY | 1 | 0.0050 |
| 1 | TOPOTECAN HYDROCHLORIDE | 2 | 0.0008 |
| 2 | MIRVETUXIMAB SORAVTANSINE | 1 | 0.0006 |
| 3 | DOSTARLIMAB | 1 | 0.0004 |
| 4 | PERTUZUMAB | 9 | 0.0003 |
| 5 | PACLITAXEL | 23 | 0.0002 |
| 6 | BEVACIZUMAB-AWWB | 1 | 0.0002 |
| 7 | CARBOPLATIN | 24 | 0.0002 |
| 8 | VINORELBINE | 1 | 0.0001 |
| 9 | DURVALUMAB | 3 | 0.0001 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Microtubule Inhibitor [EPC] | 25 | 0.0002 |
| 1 | Programmed Death Ligand-1 Blocker [EPC] | 3 | 0.0001 |
| 2 | HER2/neu Receptor Antagonist [EPC] | 10 | 0.0001 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11 | 0.0001 |
| 4 | Platinum-based Drug [EPC] | 25 | 0.0001 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 9 | 0.0000 |
| 6 | Human Immunoglobulin G [EPC] | 1 | 0.0000 |
| 7 | Bile Acid [EPC] | 1 | 0.0000 |
| 8 | Topoisomerase Inhibitor [EPC] | 3 | 0.0000 |
| 9 | Estrogen Receptor Antagonist [EPC] | 1 | 0.0000 |